Skip to content

Study of the Effects of Iron Levels on the Lungs at High Altitude

Physiology Study Investigating the Effects of Supplementation and Depletion of Iron on Hypoxia-related Pulmonary Hypertension

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00952302
Enrollment
33
Registered
2009-08-06
Start date
2008-10-31
Completion date
2008-11-30
Last updated
2009-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension, Mountain Sickness

Keywords

Hypoxia, Iron, Hypoxia-Inducible Factor 1, Chronic mountain sickness

Brief summary

The study hypothesis is that body iron levels are important in determining the increase in lung blood pressure that occurs in response to low oxygen levels. The purpose of this study is to determine whether this is true at high altitude, where oxygen levels are low.

Detailed description

Pulmonary hypertensive disorders frequently complicate hypoxic lung disease and worsen patient survival. Hypoxia-induced pulmonary hypertension is also a major cause of morbidity at high altitude. Hypoxia causes pulmonary hypertension through hypoxic pulmonary vasoconstriction and vascular remodelling. These processes are thought to be regulated at least in part by the hypoxia-inducible factor (HIF) family of transcription factors, which coordinate intracellular responses to hypoxia throughout the body. HIF is regulated through a cellular degradation process that requires iron as an obligate cofactor. In cultured cells HIF degradation is inhibited by reduction in iron (by chelation with desferrioxamine) and potentiated by iron supplementation. In humans, we have recently shown that, in laboratory experiments lasting 8 hours, acute iron supplementation blunts the pulmonary vascular response to hypoxia, while acute iron chelation with desferrioxamine enhances the response. This suggests that iron may also affect the pulmonary artery pressure response to hypoxia over longer time periods. The purpose of this study is to investigate this link between iron and the pulmonary artery pressure response to hypoxia, through a study conducted at high altitude allowing concurrent exposure of larger numbers of participants to environmental hypoxia. We wish to explore the extent and the time-course of the effect of iron on pulmonary artery pressure. Cerro de Pascu (4,340 m) in Peru provides the unique ability to make rapid transitions from sea level to high altitude (6-8 hours by road), together with the requisite research facilities. Also, one part of this study involves recruitment of patients with chronic mountain sickness, of whom there are many living in Cerro de Pasco.

Interventions

DRUGIron sucrose

Single intravenous infusion of iron 200 mg

DRUGNormal saline

Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)

PROCEDUREVenesection

Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.

Sponsors

Universidad Peruana Cayetano Heredia
CollaboratorOTHER
University of Oxford
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

SLR ARM Inclusion Criteria: * sea level natives of lowland ancestry * generally in good health * detectable tricuspid regurgitation on echocardiography

Exclusion criteria

* any significant medical problem * known susceptibility to high altitude pulmonary or cerebral oedema * taking medications or iron supplements CMS ARM Inclusion Criteria: * diagnosis of chronic mountain sickness * no recent venesection therapy (within 1 year) * detectable tricuspid regurgitation on echocardiography

Design outcomes

Primary

MeasureTime frame
Change in pulmonary artery systolic pressureOne week (SLR arm) and one month (CMS arm)

Countries

Peru

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026